HTA ID Drug Brand Indication Assessment status Date
- C1inhibitor (human) Cinryze® Treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE). Routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment Rapid Review complete 15th November 2012
- Cabazitaxel Jevtana® Treatment of patients with hormone-refractory metastatic prostate cancer previously treated with docetaxel-containing treatment regimen. NCPE Assessment process complete 13th March 2012
21026 Cabotegravir/Rilpivirine Vocabria®/Rekambys® HIV-1 infection in adults who are virologically suppressed on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class. Rapid Review complete 21st July 2021
- Cabozantinib Cabometyx® Treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. NCPE Assessment process complete 4th July 2018
22018 Cabozantinib/Nivolumab Cabometyx®/Opdivo® First-line treatment of advanced renal cell carcinoma in adults. Rapid Review complete 11th May 2022
- Cabozantinib Cometriq® Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. For patients in whom Rearranged during Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision. Rapid Review complete 13th August 2014
22063 Calcifediol monohydrate Dnord® Treatment of vitamin D deficiency (i.e., 25(OH)D levels <25 nmol/L) in adults, for the prevention of vitamin D deficiency in adults with identified risks such as in patients with malabsorption syndrome, chronic kidney disease mineral and bone disorder (CKD-MBD) or other identified risks, and as an adjuvant for the specific treatment of osteoporosis in patients with vitamin D deficiency or at risk of vitamin D deficiency. Rapid Review complete 13th October 2022
- Calcipotriol/Betamethasone dipropionate Enstilar® For the topical treatment of psoriasis vulgaris in adults Rapid review complete 22nd June 2016
- Camellia sinensis, folium (green tea leaf) Catephen® Cutaneous treatment of external genital and perianal warts (condylomataacuminata) in immunocompetent patients from the age of 18 years. Rapid Review complete 10th July 2015
- Canagliflozin Invokana® Treatment of type 2 diabetes as monotherapy or add-on combination therapy to other glucose-lowering medicinal products including insulin NCPE Assessment Process complete 29th August 2014
20004 Cannabidiol Epidyolex® As adjunctive therapy of seizures associated with Dravet Syndrome in conjunction with clobazam, for patients two years of age and older. NCPE Assessment Process complete 8th March 2021
20005 Cannabidiol Epidyolex® As adjunctive therapy of seizures associated with Lennox-Gastaut Syndrome in conjunction with clobazam, for patients two years of age and older. NCPE Assessment Process complete 8th March 2021
21024 Cannabidiol Epidyolex® As adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older. Rapid Review complete 8th July 2021
24015 Capivasertib Truqap® Capivasertib (Truqap®) is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Rapid Review Complete 29th May 2024
22013 Caplacizumab Cablivi® Treatment of adults and adolescents aged 12 years and older weighing at least 40 kg experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression. Rapid Review complete 31st March 2022
22049 Capmatinib Tabrecta® Advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. Rapid Review complete 28th February 2024
- Capsaicin Qutenza® Peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain. Rapid Review complete 2nd July 2012
20054 Carfilzomib (in combination with daratumumab and dexamethasone) Kyprolis® In combination with daratumumab and dexamethasone (CAR+DAR+DEX) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. NCPE assessment ongoing 17th June 2024
- Carfilzomib (in combination with dexamethasone) Kyprolis® For the treatment of adult patients with multiple myeloma who have received at least one prior therapy Rapid Review complete 19th March 2019
- Carfilzomib  (in combination with lenalidomide and dexamethasone)  Kyprolis® For the treatment of adult patients with multiple myeloma who have received at least one prior therapy. NCPE Assessment process complete 19th October 2016
22035 Carglumic acid Ucedane® Treatment of hyperammonaemia due to N-acetyl-glutamate synthase (NAGS) primary deficiency. Rapid Review complete 21st June 2022
- Cariprazine Reagila® For the treatment of schizophrenia in adult patients. Rapid Review complete 19th December 2018
21067 Casirivimab/imdevimab Ronapreve® For the treatment and prevention of COVID-19. Rapid Review complete 1st February 2022
- Catumazomab Removab® For the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible. Rapid Review complete 6th September 2011
22003 Cefiderocol Fetcroja® For the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. Consideration should be given to official guidance on the appropriate use of antibacterial agents. Rapid Review complete 5th June 2024
- Ceftaroline Zinforo® For the treatment of adult patients with complicated Skin and Soft Tissue Infections (cSSTI) or Community Acquired Pneumonia (CAP). Rapid Review complete 12th October 2012
- Ceftazidime/avibactam Zavicefta® For the treatment of CIAI, cUTI, HAP (including VAP) and gram negative infections due to aerobic Gram-negative organisms in adult patients with limited treatment options. Rapid Review complete 13th June 2017
21003 Ceftazidime/avibactam Zavicefta® For paediatric patients aged three months and older for the treatment of: Complicated intra-abdominal infection (cIAI); Complicated urinary tract infection (cUTI), including pyelonephritis; Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP); Infections due to aerobic Gram-negative organisms in patients with limited treatment options Rapid Review complete 4th March 2021
- Ceftolozane/tazobactam Zerbaxa® For the treatment of complicated urinary tract infections (cUTI), acute pyelonephritis and complicated intra-abdominal infections (cIAI) in adults. Rapid Review complete 26th April 2016
21007 Cemiplimab Libtayo® Is indicated as monotherapy for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation. NCPE Assessment Process Complete 24th October 2023
21025 Cenobamate Ontozry® Adjunctive treatment of focal onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinal products. NCPE Assessment Process Complete 6th July 2023
- Ceritinib Zykadia® For the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib. Rapid Review complete 22nd July 2015
- Cerliponase alfa Brineura® For the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency. NCPE Assessment process complete 26th March 2019
- Certolizumab pegol Cimzia® For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Rapid Review complete 14th November 2019
- Certolizumab pegol Cimzia® For the treatment of moderate to severe rheumatoid arthritis. NCPE Assessment Process complete 2nd September 2010
23049 Chlormethine gel Ledaga® Chlormethine gel (Ledaga®) is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients. Rapid Review Complete 20th September 2023
22033 Cholecalciferol Egostar® Prevention of vitamin D deficiency in adult patients with an identified risk, initial treatment of clinically relevant vitamin D deficiency, and as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency. Rapid Review complete 23rd June 2022
21062 Cholic acid Orphacol® For the treatment of inborn errors in primary bile acid synthesis due to 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency in infants, children and adolescents aged one month to 18 years, and adults. Rapid Review complete 12th January 2022
- Ciclosporin Ikervis® For the treatment of severe keratitis in adult patients with dry eye disease (DED), which has not improved despite treatment with tear substitutes. Rapid Review complete 18th January 2016
22021 Ciltacabtagene autoleucel Carvykti® For the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. NCPE Assessment Process Complete 27th September 2023
- Cladribine Mavenclad® For the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features NCPE Assessment process complete 20th July 2018
- Clindamycin 1% with tretinoin 0.025% Treclinac® For the topical treatment of acne vulgaris when comedones, papules and pustules are present in patients 12 years or older. Rapid Review complete 7th May 2014
19045 Co-enzyme Q10 CoQun® eye drops As a complementary add-on treatment to antihypertensive glaucoma therapy. Rapid Review complete 13th January 2020
- Cobimetinib Cotellic® For use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. NCPE Assessment process complete 5th January 2017
- Colesevelam Cholestagel® Hypercholesterolaemia Rapid Review complete 22nd October 2010
- Colistimethate sodium Colobreathe® For the management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older. Rapid Review complete 28th June 2013
- Collagenase Clostridium Histolyticum Xiapex® Treatment of Dupuytren’s contracture in adult patients with a palpable cord. Rapid Review complete 9th June 2011
21017 Conestat alfa Ruconest® For the treatment of acute angioedema attacks in adults, adolescents, and children (aged 2 years and above) with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency. Rapid Review complete 2nd June 2021
- Corifollitropin alfa Elonva® Controlled Ovarian Stimulation (COS) in combination with a Gonadotropin Releasing Hormone (GnRH) antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program. Rapid Review complete 22nd October 2010
- Crizotinib Xalkori® Treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (i.e. in the 2nd / 3rd–line treatment setting) NCPE Assessment process complete 27th August 2013